Outcomes and Therapeutic Management of Bladder Cancer 

<br/><br/><br/>English[eng] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>bladder cancer||robotic-assisted||open||radical cystectomy||survival||propensity score||age||urothelial carcinoma||outcome||anesthesia recovery periods||cognitive impairment||gamma-cyclodextrins||neuromuscular blockade||robotic radical cystectomy||glycogen||clear-cell adenocarcinoma||urinary bladder||SEER program database||female||intracorporeal neobladder||outcomes||robotic||sex-sparing||methylation||biomarkers||FOXA1||GATA3||KRT20||molecular markers||mRNA||muscle-invasive bladder cancer||PCR||human epidermal growth factor receptor 2||indoleamine 2,3-dioxygenase||programmed death ligand-1||immunotherapy||nodal disease||pN1||neoadjuvant||adjuvant||chemotherapy||n/a